December 9, 2020 Company announces $24 million Series A financing and appoints Jason T. Gammack as CEO to accelerate development and commercialization of Molecular Cartography TM platform
MONHEIM AM RHEIN, Germany – Dec. 10, 2020 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced the completion of a $24 million Series A financing round and the appointment of Co-founder Jason T. Gammack as Chief Executive Officer.
The company's Molecular Cartography platform is a groundbreaking multi-analyte and highly multiplex spatial analysis technology that enables scientists to resolve the most daunting biological challenges in areas such as oncology, neuroscience, and infectious disease. It produces deep contextual data sets that illuminate molecular interactions at subcellular resolution, while preserving the sample tissue. The initial applications of Resolve's Molecular Cartography platform deliver the highest-resolution view of transcriptomic activity and provide the ability to interrogate hundreds of genes in a single run. Futuresolutions will add DNA, protein, and metabolomic data layers. Unlike current approaches, Resolve's technology provides the required sensitivity, specificity, and workflow convenience to elucidate the cell's complex transcriptional landscape.